REGN
$759.05
Regeneron Pharmaceuticals, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, ...
Recent News
Is Pfizer Inc. (PFE) One of Goldman Sachs Top Healthcare Stocks?
Pfizer Inc. (NYSE:PFE) is one of Goldman Sachs top healthcare stocks. On March 9, analysts at BMO reiterated an Outperform rating on Pfizer Inc. (NYSE:PFE) and a $30 price target. The bullish stance follows positive phase 2 data on the company’s tri-specific antibody tilrekimig. Trial results showed that the once-a-month inhibitor achieved a placebo-adjusted high […]
Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy?
Is REGN a good stock to buy? We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Ocular Capital’s Substack. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.’s share was trading at $774.66 as of March 11th. REGN’s trailing and forward P/E were 18.68 and 18.05, respectively according to Yahoo Finance. […]
Assessing Illumina (ILMN) Valuation After Expanded Genomics And Proteomics Alliance With Regeneron
Illumina (ILMN) is back in focus after expanding its Alliance for Genomic Discovery with Regeneron Genetics Center and launching a dataset of more than 50,000 genomes plus proteomic data using Illumina Protein Prep, targeting multiomic drug discovery research. See our latest analysis for Illumina. Despite the latest alliance news, Illumina’s share price at US$118.94 reflects mixed momentum, with a 2.92% 1 day share price return but a 90 day share price return decline of 11.84%. The 1 year...
3 Profitable Stocks We Think Twice About
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Health Care Roundup: Market Talk
Find insight on Celltrion, Sanofi, Roche Holding and more in the latest Market Talks covering Health Care.